Page 2 - Integrated Research News Today

Jacobs and its subcontractors were instrumental in the Missile Defense Agency's flight demonstration of Ground-based Midcourse Defense Weapon System-12 interceptor against an intermediate-range ballistic missile. Jacobs, which leads the Integrated Research and Development for Enterprise Solutions contract, said Wednesday that it deployed employees in different locations to provide IT services, connectivity and communications for the flight test.

From work using virtual reality to studies carried out in space, scientists are hoping to build a future free from arthritis and its symptoms, with a charity investing millions

Stephen J. Freedland, MD, discusses the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

 From property investment & development to hotels and resorts as well as providing multi-services for all its products, PT Patra Jasa led by its ...

Kenya’s tourism authorities have made it easier to reach the uppers slopes of Mount Kenya, and plan to further improve access. Critics say they risk making the mountain as polluted as Kilimanjaro.

Multiple surveys of patient-reported outcomes from the phase 3 EMBARK trial revealed no meaningful differences in pain progression or urinary symptoms and bowel symptoms or function over 205 weeks of follow-up. Enzalutamide does not worsen health-related quality of life compared with androgen deprivation therapy in patients with high-risk biochemically recurrence nmCSPC.

In Meru county, environmental experts are sounding an alarm over the dwindling of water resources especially in the Mt Kenya ecosystem, one of Kenya's water towers.

Rice University today announced the addition of Kevin Sheridan to its external advisory board for the Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of the university’s health and medical technology discove

Enzalutamide plus androgen deprivation therapy or alone can extend metastasis-free survival and maintain quality of life in men with prostate cancer facing a high-risk for biochemical recurrence.

ERS Genomics, co-founded by Dr. Emmanuelle Charpentier, a recipient of the 2020 Nobel Prize in Chemistry for her pioneering work on CRISPR/Cas9, provides access to the definitive patent portfolio for this groundbreaking technology.